Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | +3.21% | -9.53% | +72.71% |
May. 14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.71% | 34.33M | |
+47.52% | 58.06B | |
-6.10% | 40.53B | |
+37.69% | 38.99B | |
+12.93% | 26.7B | |
-12.01% | 26.56B | |
-21.70% | 18.98B | |
+0.98% | 12.17B | |
+22.24% | 12B | |
+25.38% | 11.92B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target